NOSSAMAN LLP for AMERISOURCEBERGEN CORPORATION (FORMERLY "AMERISOURCEBERGEN SPECIALTY GROUP")
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
H.R.905 and S.733, legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. ASP Generally (in the context of deficit reduction).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHELBY LYNNE HAGENAUER | — |
| BRENT HEBERLEE | — |
| TIMOTHY W JENKINS | — |
| SHERRY HARPER WIDICUS | — |
Taxation/Internal Revenue Code TAX
Repeal of LIFO (Last in, First Out).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHELBY LYNNE HAGENAUER | — |
| BRENT HEBERLEE | — |
| TIMOTHY W JENKINS | — |
| SHERRY HARPER WIDICUS | — |
Pharmacy PHA
H.R.905 and S.733, legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1483, H.R.3026 and S.1584, pharmaceutical pedigree anti-counterfeiting legislation. H.R.2245 and S.296, legislation pertaining to drug manufacturing shortages.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHELBY LYNNE HAGENAUER | — |
| BRENT HEBERLEE | — |
| TIMOTHY W JENKINS | — |
| SHERRY HARPER WIDICUS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.